Transition from systemic lupus erythematosus to common variable hypogammaglobulinemia

Area of Science:

• Immunology
• Rheumatology

Background:

• Systemic lupus erythematosus (SLE) is a complex autoimmune disease characterized by B cell hyperactivity and autoantibody production.
• B cell dysfunction in SLE can manifest in various ways, impacting immunoglobulin levels and immune responses.

Observation:

• A 34-year-old male patient initially presented with SLE, exhibiting high antinuclear antibody titers and elevated IgG levels.
• Following immunosuppressive therapy for SLE, the patient experienced a significant decrease in serum IgG and IgA levels.
• Years later, this patient developed panhypogammaglobulinemia, characterized by recurrent sinopulmonary infections and nodular lymphoid hyperplasia.

Findings:

• Serial immunoglobulin measurements in 13 other SLE patients revealed transient, treatment-related decreases in immunoglobulin levels.
• High-dose prednisone therapy, more so than cytotoxic drugs, correlated with reduced immunoglobulin concentrations in SLE patients.
• The patient's transition from SLE to common variable hypogammaglobulinemia underscores a potential, albeit rare, complication of SLE treatment.

Implications:

• This case suggests a link between intensive immunosuppressive treatment for SLE and the development of secondary hypogammaglobulinemia.
• Understanding this association is crucial for managing SLE patients, particularly regarding monitoring immunoglobulin levels and infection risk.
• Further research is warranted to elucidate the mechanisms underlying B cell dysfunction progression from SLE to hypogammaglobulinemia.